TradeUP Acquisition Corp. prices $40M IPO; 4M units at $10 each

Estrella Immunopharma, Inc.

IPO of 4,000,000 units at $10.00/unit, gross proceeds of $40 million; over-allotment option of 600,000 units available.
Private placement of 295,000 shares to founders at $10/share, raising $2.95 million concurrent with IPO closing.
Net proceeds of $40.8 million ($40M IPO + $0.8M private placement) placed in trust account for business combination.
Board classified: Weston Twigg (Class I, 2022), Tao Jiang & James Long (Class II, 2023), Jianwei Li & Weiguang Yang (Class III, 2024).
Units listed on Nasdaq under UPTDU starting July 15; common stock (UPTD) and warrants (UPTDW) will trade separately later.

item 1.01 item 3.02 item 5.02 item 5.03 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James Long

Director

ESLA · Estrella Immunopharma, Inc.

Effective: 2021-07-14
Filed: July 19, 2021, 7:59 PM ET

Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.

Appointed

Weston Twigg

Director

ESLA · Estrella Immunopharma, Inc.

Effective: 2021-07-14
Filed: July 19, 2021, 7:59 PM ET

Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.

Appointed

Tao Jiang

Director

ESLA · Estrella Immunopharma, Inc.

Effective: 2021-07-14
Filed: July 19, 2021, 7:59 PM ET

Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

James Long was appointed as Director at Estrella Immunopharma, Inc..

Action: became director
Role: Director

Exact text from the filing

Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Weston Twigg was appointed as Director at Estrella Immunopharma, Inc..

Action: became director
Role: Director

Exact text from the filing

Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Tao Jiang was appointed as Director at Estrella Immunopharma, Inc..

Action: became director
Role: Director

Exact text from the filing

Effective July 14, 2021, in connection with the effectiveness of the Registration Statement, Weston Twigg, Tao Jiang and James Long became directors of the Company.

View on SEC.gov

Estrella Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-093550

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.